Ocular Changes With Alpha-2 Receptor Agonist.

Last updated: January 2, 2023
Sponsor: Benha University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Ocular Hypertension

Treatment

N/A

Clinical Study ID

NCT05670015
RC-2-2023
  • Ages 18-50
  • All Genders

Study Summary

selective alpha-2 receptor agonists cause changes in intraocular pressure and pupillary size thus may affect patient quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Glaucoma suspect cases.
  • post-refractive surgery cases.

Exclusion

Exclusion Criteria:

  • Cases with prostatic hyperplasia or diabetics that may alter the measurements ofpupillary diameter.
  • Cases with previous history of any retinal intervention or other drugs that may alterintraocular pressure measurements.

Study Design

Total Participants: 150
Study Start date:
January 01, 2023
Estimated Completion Date:
September 22, 2023

Study Description

In this research, we will analyze the effect of selective alpha-2 receptor agonists on the human eye and investigate ocular changes over 6 months after its topical use.

Connect with a study center

  • Ahmed Abdelshafy

    Banhā, QA 13511
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.